knowledge -WSS

knowledge

author：focus 2025-09-06 02:16:18 - browse：86859

Teleflex announced plans on Wednesday to acquire Palette Life Sciences, the maker of a slate of gel-based products treating urological disorders. The vascular device manufacturer will pay $600 million upfront, and plans to use Palette’s portfolio to treat more urinary tract and reproductive health conditions.

Palette will bring Teleflex an extra $56 million in sales, the company estimated in a press release. Teleflex develops a range of devices, but makes the most money from vascular products like catheters. The company offers just one urological treatment: the UroLift system to relieve an enlarged prostate. With Palette, it will gain five more treatments all built from hyaluronic acid, a stretchy material that’s meant to last longer in the human body.

Palette’s highest-revenue device is Barrigel, which helps protect the rectum from harsh radiation administered to prostate cancer patients. It eases symptoms like bladder inflammation, bleeding, and diarrhea. The device received FDA clearance in May 2022 through the 510(k) process, which allowed Palette to claim the product was equivalent to a rectal radiation protector sold by Boston Scientific. Boston Scientific has sold that device since 2018, when it acquired it by buying the startup Augmenix for $500 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： Bird flu outbreak in cows is latest avian flu curveball

explore

WSS

How to improve immunocompromised access to mAb treatments

Software glitch causes Tandem insulin pump to shutdown, FDA warns

'Hero' Louisville officer shot in head at mass shooting discharged over 3 months later

Will biotech layoffs continue through 2023?

Interest rates are at a 22

Use wet bulb globe temperature, not heat index, to protect workers

hotspot

knowledge

hotspot

Medicare proposal to cover medical devices draws a mixed reaction

Elevance, private equity launch primary care company

Bright Health sells Medicare Advantage business to Molina

Public health communication lessons from Covid

Dobbs anniversary: the lost opportunity of abortion as health care

How to improve immunocompromised access to mAb treatments

Hepatitis C has a cure — but many Americans still lack access to it

H5N1 communication has been strictly for the birds

At least 13 dead in Texas as scorching temps continue

First recipient of genetically engineered pig kidney has died

focus

How to improve immunocompromised access to mAb treatments

Bryan Kohberger seeks indictment dismissal in Idaho college killings case

Moscow blames Kyiv for missile attacks in southern Russia as Kremlin forces pound Ukrainian village

Steward Health Care files for bankruptcy

‘We were in the air.’ Mississippi family recounts surviving tornado that tore mobile home apart

Shionogi licenses Pompe disease therapy from Maze Therapeutics

explore

explore

explore

leisure time